Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Retained Earnings (2016 - 2026)

Tenax Therapeutics' Retained Earnings history spans 6 years, with the latest figure at -$213.5 million for Q4 2017.

  • On a quarterly basis, Retained Earnings fell 4.32% to -$213.5 million in Q4 2017 year-over-year; TTM through Dec 2017 was -$213.5 million, a 4.32% decrease, with the full-year FY2017 number at -$213.5 million, down 4.32% from a year prior.
  • Retained Earnings hit -$213.5 million in Q4 2017 for Tenax Therapeutics, down from -$212.2 million in the prior quarter.
  • Over the last five years, Retained Earnings for TENX hit a ceiling of -$115.2 million in Q1 2013 and a floor of -$213.5 million in Q4 2017.
  • Historically, Retained Earnings has averaged -$178.8 million across 4 years, with a median of -$189.8 million in 2016.
  • Biggest five-year swings in Retained Earnings: dropped 27.33% in 2016 and later dropped 4.32% in 2017.
  • Tracing TENX's Retained Earnings over 4 years: stood at -$117.0 million in 2013, then plummeted by 37.33% to -$160.7 million in 2015, then decreased by 27.33% to -$204.7 million in 2016, then decreased by 4.32% to -$213.5 million in 2017.
  • Business Quant data shows Retained Earnings for TENX at -$213.5 million in Q4 2017, -$212.2 million in Q3 2017, and -$210.9 million in Q2 2017.